Multiparametric prediction models for moderate to severe thyroid-associated eye disease
Official title: Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy
Run by Shanghai Changzheng Hospital · NCT06590220 · Data updated 2026-11-12
This project will try to build and test combined imaging and lab-marker models to predict outcomes in adults with moderate to severe thyroid-associated ophthalmopathy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Shanghai Changzheng Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | October 9, 2024 |
| Main results expected | September 6, 2026 |
| Study ends | September 6, 2028 |
| Registry record updated | June 24, 2025 |
| Trial ID | NCT06590220 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with moderate to severe TAO meeting Bartley and EUGOGO criteria with CAS ≥3 in the study eye, who have not received high cumulative systemic steroids for TAO and can attend Shanghai Changzheng Hospital, are ideal candidates.
✕Probably not a fit
Patients needing immediate sight‑saving interventions, those with prior high cumulative steroid treatment for TAO, or those with major unstable illnesses are unlikely to gain benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers at Shanghai Changzheng Hospital will enroll adults diagnosed with moderate to severe TAO (Bartley and EUGOGO definitions, CAS ≥3) and collect clinical data, multimodal imaging, and laboratory markers. The observational protocol will use these multimodal inputs to train multiparametric statistical and machine-learning models aimed at predicting disease course and treatment needs. Models will be developed on one set of participants and validated on another to measure predictive accuracy and generalizability. No investigational treatments are given as part of participation; involvement focuses on data and imaging collection.
Why it matters
Potential benefit: If successful, the prediction models could help clinicians choose the right treatments earlier and reduce the risk of vision‑threatening complications.
How similar studies have gone: Prior research has found individual imaging features and biomarkers linked to TAO activity, but comprehensive multiparametric prediction models are relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * According to the Bartley criteria，diagnosed TAO at our hospital after 2024/8/31 * Moderate to severe patients defined by EUGOGO * CAS ≥3 (on the 7-item scale) for the study eye Exclusion Criteria: * Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision * History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \>1 g of methylprednisolone for the treatment of TAO. * Any major illness/condition or evidence of an unstable clinical condition that, in the investigator\'s judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study * Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant\'s participation in the study * Pregnant or lactating * Any other condition that,would impair the ability of the participant to undergo orbital MRI * Incomplete information
Where it's running
-
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Tuo Dr. Li, Vice Professor
- Email: dr.lituo@smmu.edu.cn
- Phone: +86-13918507887
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Precise diagnosis and treatment system for thyroid-associated eye disease
This project will test whether a deep-learning system using eye images and exams can automatically diagnose, stage, and help plan treatment for people with thyroid-associated ophthalmopathy.
-
Combining Tocilizumab and Flupentixol-Melitracen for Thyroid Eye Disease Treatment
This study is testing if combining two medications, Tocilizumab and Flupentixol-Melitracen, can help people with thyroid eye disease feel better and improve their eye symptoms.
-
Comparing short and standard radiation therapy for thyroid eye disease
This study is testing if fewer sessions of radiation therapy can help people with moderate to severe thyroid eye disease just as well as the standard number of sessions, while also making their experience better.
-
Evaluating linsitinib for thyroid eye disease
This study is testing if a new drug called linsitinib can help people with moderate to severe thyroid eye disease who haven't improved with other treatments.
-
Evaluating doxycycline for treating Thyroid Associated Ophthalmopathy
This study is testing if doxycycline can help people with Thyroid Associated Ophthalmopathy feel better and improve their eye symptoms.
-
Comparing Sirolimus and Corticosteroids for Thyroid Eye Disease
This study tests whether Sirolimus can be a safer and more effective treatment for people with moderate-to-severe thyroid eye disease compared to traditional corticosteroids.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.